Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Schuster SJ, et al. Among authors: janakiram m. Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10. Lancet Oncol. 2021. PMID: 34516954 Clinical Trial.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A, Peeke S, Shah N, Mustafa J, Khatun F, Lombardo A, Abreu M, Elkind R, Fehn K, de Castro A, Wang Y, Derman O, Nelson R, Uehlinger J, Gritsman K, Sica RA, Kornblum N, Mantzaris I, Shastri A, Janakiram M, Goldfinger M, Verma A, Braunschweig I, Bachier-Rodriguez L. Abbasi A, et al. Among authors: janakiram m. J Hematol Oncol. 2020 Jan 3;13(1):1. doi: 10.1186/s13045-019-0838-y. J Hematol Oncol. 2020. PMID: 31900191 Free PMC article.
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Hayes-Lattin B, Janakiram M, Maziarz RT, McGuirk JP, Nastoupil LJ, Oluwole OO, Perales MA, Porter DL, Riedell PA; CAR T-cell Consortium. Bachanova V, et al. Among authors: janakiram m. Biol Blood Marrow Transplant. 2020 Jul;26(7):1239-1246. doi: 10.1016/j.bbmt.2020.04.008. Epub 2020 Apr 14. Biol Blood Marrow Transplant. 2020. PMID: 32298807 Free PMC article. Review.
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Epperla N, et al. Among authors: janakiram m. J Hematol Oncol. 2022 Jul 16;15(1):96. doi: 10.1186/s13045-022-01316-1. J Hematol Oncol. 2022. PMID: 35842643 Free PMC article.
Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma.
Savani M, Gencturk M, Shanley R, Cayci Z, Wilke C, Warlick ED, He F, Janakiram M, Weisdorf DJ, Brunstein CG, Bachanova V. Savani M, et al. Among authors: janakiram m. Biol Blood Marrow Transplant. 2020 Feb;26(2):272-277. doi: 10.1016/j.bbmt.2019.10.013. Epub 2019 Oct 24. Biol Blood Marrow Transplant. 2020. PMID: 31669174 Free article.
Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.
Allred J, Bharucha K, Özütemiz C, He F, Janakiram M, Maakaron J, Carrier C, Grzywacz B, Bachanova V. Allred J, et al. Among authors: janakiram m. Bone Marrow Transplant. 2021 Mar;56(3):679-682. doi: 10.1038/s41409-020-01018-7. Epub 2020 Aug 6. Bone Marrow Transplant. 2021. PMID: 32764581 Free PMC article. No abstract available.
Effect of Keratinocyte Growth Factor on Hospital Readmission and Regimen-Related Toxicities after Autologous Hematopoietic Cell Transplantation for Lymphoma.
El Jurdi N, Fair C, Rogosheske J, Shanley R, Arora M, Bachanova V, Betts B, He F, Holtan S, Janakiram M, Maakaron J, Rashidi A, Warlick E, Weisdorf D, Brunstein CG. El Jurdi N, et al. Among authors: janakiram m. Transplant Cell Ther. 2021 Feb;27(2):179.e1-179.e4. doi: 10.1016/j.jtct.2020.11.005. Epub 2020 Dec 13. Transplant Cell Ther. 2021. PMID: 33830033 Free article.
90 results